Serelaxin (Serelaxinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Vasodilators

Included in the formulation
  • Reassures
    concentrate d / infusion 
    Novartis Pharma AG     Switzerland
    • АТХ:

    C.01.D   Peripheral vasodilators used to treat heart disease

    Pharmacodynamics:

    Has a pharmacotherapeutic effect in chronic congestive heart failure due to a decrease in preload and afterload on the heart. Both capacitive and resistive vessels expand.

    Pharmacokinetics:

    The equilibrium concentration in the blood serum is reached 4-6 hours after the onset of IV infusion. The main way of metabolism, apparently, is the catabolism of peptidases and proteases in various tissues of the body, including the liver and kidneys.

    Serelaxin is rapidly excreted from the body. Half-life at the end of intravenous administration is from 7 to 15.9 hours.

    The age of the patients does not affect the pharmacokinetics of serlaxine.

    Indications:

    Acute congestive heart failure in patients with normal or elevated blood pressure simultaneously with standard therapy of acute heart failure, incl. "looped" diuretics.

    ICD-10

    IX.I30-I52.I50.1   Left ventricular failure

    Contraindications:

    Shock of different etiologies; obstruction of the outflow tract of the left ventricle (including aortic stenosis of severe degree,hypertrophic obstructive cardiomyopathy); children and adolescents under 18; increased sensitivity to sulfuraxine.

    Carefully:

    In children, efficacy and safety have not been studied.

    Pregnancy and lactation:

    FDA recommendation category C.

    In pregnancy, use is only possible in cases where the expected benefit to the mother exceeds the potential risk to the fetus. At the time of reception, stop breastfeeding.

    Dosing and Administration:

    Only in a hospital.

    Enter as a continuous IV infusion for 48 hours.

    The recommended dose is 30 mcg / kg / day. Correction of the dose is carried out depending on the clinical situation.

    Before the administration of sulfuraxine, systolic blood pressure should be stabilized at a level of more than 125 mm Hg.

    Side effects:

    From the side of the cardiovascular system: often - a marked decrease in blood pressure.

    Overdose:

    Not described.

    Interaction:

    In clinical studies with the use of silveraxin concomitantly with digoxin, there was no clinically significant effect on the clearance of serlaxine.

    Special instructions:

    In connection with the risk of a marked decrease in blood pressure during the administration of sulfuraxine, BP should be monitored regularly.

    Stop use when the SBP decreases below 100 mmHg.

    In accordance with clinical recommendations, use with caution at the same time as vasodilating and / or antihypertensive agents.

    Due to the lack of clinical data for use in patients with severe renal dysfunction, the question of the use of the drug should be considered only if the expected benefit of the treatment exceeds the possible risk.

    Store in a dark place at a temperature of 2-8 ° C (do not freeze).

    Instructions
    Up